| 规格: | 98% |
| 分子量: | 446.92 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
[1]. Daewoong speeds up developing antidiabetic Enavogliflozin
[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin
[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong’s Enavogliflozin & Janssen Biotech’s Golimumab Among Others - ResearchAndMarkets.com
m.cnreagent.com